Ken Griffin Annexon, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $909,225 - $1.46 Million	-202,500 Reduced 83.09%	41,200 $243,000
Q2 2024 Aug 14, 2024	BUY	$4.33 - $6.79 $319,554 - $501,102	73,800 Added 43.44%	243,700 $1.19 Million
Q1 2024 May 15, 2024	BUY	$4.03 - $7.81 $638,755 - $1.24 Million	158,500 Added 1390.35%	169,900 $1.22 Million
Q4 2023 Feb 14, 2024	SELL	$1.63 - $4.63 $11,736 - $33,336	-7,200 Reduced 38.71%	11,400 $51,000
Q3 2023 Nov 14, 2023	SELL	$2.13 - $3.84 $68,586 - $123,648	-32,200 Reduced 63.39%	18,600 $43,000
Q2 2023 Aug 14, 2023	SELL	$2.1 - $6.37 $233,100 - $707,070	-111,000 Reduced 68.6%	50,800 $178,000
Q1 2023 May 15, 2023	SELL	$3.74 - $7.46 $3,740 - $7,460	-1,000 Reduced 0.61%	161,800 $622,000
Q4 2022 Feb 14, 2023	BUY	$4.56 - $6.61 $378,479 - $548,630	83,000 Added 104.01%	162,800 $841,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $6.63 $119,250 - $210,834	31,800 Added 66.25%	79,800 $493,000

146

102M

178K

159K

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $244M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.